Business
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025, to $896 millionFDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL Remained focused on disciplined investment in our late-stage portfolio, EPKINLY® (epcoritamab), Rina-S®, and petosemtamab, including launch readiness “We made tangible progr
About this update from Genmab A/s
[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AGO7EVEtSEHL6RvrRWW5kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AGO7EVEtSEHL6RvrRWW5kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026","length":90,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genmab revenue increased 25% compared to the first three months of 2025, to $896 million","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL ","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Remained focused on disciplined investment in our late-stage portfolio, EPKINLY® (epcoritamab), Rina-S®, and petosemtamab, including launch readiness","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"“We made tangible progress in the first quarter as we continue to integrate Merus™ and advance our late-stage portfolio - EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.","length":408,"tagName":"p"},{"type":"text","content":"Financial Performance First Three Months of 2026","length":48,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue was $896 million for the first three months of 2026 compared to $715 million for the first three months of 2025. The increase of $181 million, or 25%, was primarily dr...